Passport Capital’s Acceleron Pharma XLRN Stock Holding History

Passport Capital’s Portfolio XLRN Stock Details XLRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q2	–	Sell	-5,845	Closed	-$202K	–	261
2014 Q1	$202K	Buy	+5,845	New	+$264K	0.01%	155

Other funds holding XLRN

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

PVMCI

Polaris Venture Management Co IV Boston, Massachusetts $62.4M AUM 33.04% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

SAM

Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Passport Capital's XLRN Position: Q2 2014 in Review

Passport Capital sold out of Acceleron Pharma (XLRN) in Q2 2014, closing a stake of 5,845 shares — an estimated $202K sold.

Passport Capital first reported a position in XLRN in Q1 2014 and held it in 1 quarter. The position peaked at $202K in Q1 2014. 91 funds tracked by Wall St. Rank hold XLRN as of Q2 2014.

Passport Capital reported no remaining Acceleron Pharma position as of Q2 2014 after selling out during the quarter.
Passport Capital sold 5,845 Acceleron Pharma shares in Q2 2014, an estimated $202K.
Passport Capital first reported a position in Acceleron Pharma in Q1 2014 and held it in 1 quarter.
Passport Capital's Acceleron Pharma position peaked at $202K in Q1 2014.
91 funds tracked by Wall St. Rank held Acceleron Pharma as of Q2 2014.

Based on Passport Capital's 13F filing for Q2 2014, filed 14 Aug 2014.